Since then, the hypothesis that BCL-2 contributes to SCLC survival has been studied; however, only recently with the advent of venetoclax has this hypothesis been able to be pharmacologically tested with a specific BCL-2 inhibitor. This evidence concerns the gene BCL2 and small cell lung carcinoma.